By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue
Suite 100
Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817


SEARCH JOBS




Collaborations

AVANIR 





Company News
Peregrine (PPHM) Highlights Clinical Data Presentation At AACR 2017 Annual Meeting Supporting Potential Of Bavituximab To Enhance Anti-Tumor Activity Of Immunotherapy 4/4/2017 12:01:39 PM
Peregrine (PPHM) Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities 4/3/2017 1:37:27 PM
Peregrine (PPHM) Reports Financial Results For The Third Quarter Of Fiscal Year 2017 And Recent Developments 3/14/2017 11:00:17 AM
Peregrine (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 3/10/2017 10:59:06 AM
Peregrine (PPHM) To Report Financial Results For Third Quarter Of Fiscal Year 2017 After Market Close On March 13, 2017 3/6/2017 10:32:13 AM
Peregrine (PPHM) Release: Recent Publication Highlights Proof-Of-Concept Data Supporting The Diagnostic Potential Of Phosphatidylserine-Positive Exosomes In Ovarian Cancer 2/9/2017 7:53:36 AM
Peregrine (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 12/7/2016 8:20:28 AM
Peregrine (PPHM) To Report Financial Results For Second Quarter Of Fiscal Year 2017 After Market Close On December 12, 2016 12/6/2016 7:26:12 AM
New Study Demonstrates Anti-Tumor Advantages For Combination Treatment Featuring Peregrine (PPHM)’ PS-Targeting Antibodies In A Preclinical Melanoma Model 11/14/2016 7:52:22 AM
Preclinical Research Demonstrates Peregrine (PPHM)’ PS-Targeting Antibodies Enhance The Anti-Tumor Activity Of PD-L1 Checkpoint Inhibitors In Model Of Triple Negative Breast Cancer (TNBC) 10/24/2016 8:04:38 AM
12345678910...
//-->